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Microglia are resident innate immune cells which release many factors including
proinflammatory cytokines, nitric oxide (NO) and neurotrophic factors when they are
activated in response to immunological stimuli. Recent reports show that pathophysiology
of schizophrenia is related to the inflammatory responses mediated by microglia.
Intracellular Ca2+ signaling, which is mainly controlled by the endoplasmic reticulum (ER),
is important for microglial functions such as release of NO and cytokines, migration,
ramification and deramification. In addition, alteration of intracellular Ca2+ signaling
underlies the pathophysiology of schizophrenia, while it remains unclear how typical
or atypical antipsychotics affect intracellular Ca2+ mobilization in microglial cells. This
mini-review article summarizes recent findings on cellular mechanisms underlying the
characteristic differences in the actions of antipsychotics on microglial intracellular Ca2+
signaling and reinforces the importance of the ER of microglial cells as a target of
antipsychotics for the treatment of schizophrenia.
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INTRODUCTION
Microglia are immune cells which are derived from progen-
itors that have migrated from the periphery and are from
mesodermal/mesenchymal origin (Kettenmann et al., 2011).
After invading the brain parenchyma, microglia transform into
the “resting” ramified phenotype and are distributed in the
whole brain. However, microglia revert to an ameboid appear-
ance when they are activated in the disturbances including
infection, trauma, ischemia, neurodegenerative diseases or any
loss of brain homeostasis (Aguzzi et al., 2013; Cunningham,
2013). Recent in vivo imaging has shown that microglial
cells actively scan their environment with motile protrusions
even in their resting state and are ready to transform to
“activated” state in responses to injury, ischemia or autoim-
mune challenges in the brain (Wake et al., 2013). Microglia
can release many factors including proinflammatory cytokines
(such as TNFα, IL-6), nitric oxide (NO) and neurotrophic fac-
tors (such as BDNF) when they are activated in response to
immunological stimuli (Kettenmann et al., 2011; Smith and
Dragunow, 2014). In addition, microglia are shown to be involved
in the development of neural circuits or synaptic plasticity
thereby maintaining the brain homeostasis (Schwartz et al.,
2013).
There is increasing evidence suggesting that pathophysiol-
ogy of schizophrenia is related to the inflammatory responses
mediated by microglia (Müller and Schwarz, 2007; Kato et al.,
2011; Monji et al., 2013; Myint and Kim, 2014). A recent meta-
analysis of associations between schizophrenia and dysfunction
of immune systems including aberrant circulating cytokine levels
showed that IL-1β, IL-6 and transforming growth factor-β
(TGF-β) appeared to be state markers, as they were elevated
in acutely relapsed inpatients or in first-episode psychosis and
then normalized with antipsychotic medications. In contrast,
IL-12, interferon-γ (IFNγ) and tumor necrosis factor α (TNFα)
appeared to be trait markers, as they remained elevated in
acute exacerbations of psychotic symptoms and even after the
antipsychotic treatment (Miller et al., 2011). Microglial acti-
vation can be estimated by positron emission tomography
(PET) using radiopharmaceuticals. For example, a quantitative
(R)-[(11)C]PK11195 PET scan showed that activated microglia
were present in the gray matter of patients suffered from
schizophrenia within the first 5 years of disease onset (van
Berckel et al., 2008). Another PET study using [11C]DAA1106
showed a positive correlation between cortical [11C]DAA1106
binding and positive symptom scores obtained from patients with
schizophrenia (Takano et al., 2010). In addition, we and others
have reported that pretreatment with antipsychotics significantly
inhibits the release of proinflammatory cytokines and/or NO
from activated microglial cells (Hou et al., 2006; Kato et al.,
2013). Interestingly, pretreatment with haloperidol or risperidone
significantly suppressed the release of proinflammatory cytokines
and NO from activated microglial cells, although the inhibitory
effects of risperidone were much stronger than those of haloperi-
dol (Kato et al., 2007). In addition, we have previously shown
that pretreatment with aripiprazole suppressed the elevation of
intracellular Ca2+ concentration ([Ca2+]i) induced by IFNγ in
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microglial cells, suggesting the importance of microglial intracel-
lular Ca2+ signaling as a target of antipsychotics for the treatment
of schizophrenia (Kato et al., 2008; Mizoguchi et al., 2011),
because elevation of intracellular Ca2+ is important in activation
of microglial cell functions, including proliferation, release of
NO and cytokines, migration, ramification and deramification
(Färber and Kettenmann, 2006). Here, we briefly review our
current understanding of the cellular mechanisms underlying
the characteristic differences in the actions of antipsychotics on
neuronal or microglial intracellular Ca2+ signaling and rein-
forces the importance of the endoplasmic reticulum (ER) of
microglial cells as a target of antipsychotics for the treatment of
schizophrenia.
SCHIZOPHRENIA AND INTRACELLULAR Ca2+ SIGNALING
The electrical activity of neurons (i.e., excitable cells) depends
on a number of different types of voltage- or ligand-gated ion
channels that are permeable to inorganic ions such as sodium,
potassium, chloride and calcium. While the former three ions
predominantly support the electrogenic role, Ca2+ are different in
that they can not only alter the membrane potential but also serve
as important intracellular signaling entities by themselves. In the
CNS, intracellular Ca2+ signaling regulates many different neu-
ronal functions, such as cell proliferation, gene transcription and
exocytosis at synapses (Berridge et al., 2003). In neurons, because
the prolonged elevation of [Ca2+]i is cytotoxic, [Ca2+]i is tightly
regulated by intrinsic gating processes mediated by voltage-gated
calcium channels and NMDA receptors (NMDARs; Simms and
Zamponi, 2014). In addition, dysregulation of neuronal Ca2+
signaling have been linked to various neuropsychiatric disorders
including schizophrenia (Lidow, 2003). A possible involvement
of intracellular Ca2+ signaling in schizophrenia was originally
presented by Jimerson et al. (1979), based on their finding
that remission from acute psychotic symptoms of schizophrenia
was accompanied by elevation of the Ca2+ concentration in
the cerebrospinal fluid. Thereafter, the interaction of neuronal
dopaminergic transmission and intracellular Ca2+ signaling was
documented. Dopamine D2 receptors were shown to be regu-
lated by intracellular Ca2+ through the activation of CaMKII
or neuronal Ca2+ sensor 1 (NCS-1). Both CaMKII and NCS-1
have also been reported to be involved in the pathophysiology of
schizophrenia (Bai et al., 2004; Luo et al., 2014). Another topic
of hypothesis underlying the pathophysiology of schizophrenia
is the involvement of intracellular Ca2+signaling within the fast
spiking GABAergic inhibitory neurons in the hypofunction of
NMDARs which leads to the dysfunction of GABAergic inhibitory
circuits (Lewis et al., 2005; Berridge, 2013). The sustained and
synchronous firing of dorsolateral prefrontal cortical neurons in
the gamma frequency range of approximately 40 Hz (gamma
rhythms) depends on excitatory pyramidal neurons which release
glutamate to activate the inhibitory GABAergic interneurons. The
hypofunction of NMDARs results in the reduction of intracellular
Ca2+ signaling, suppression of the induction of transcription
factor CREB and reduction in the expression of the glutamic acid
decarboxylase 67 (GAD67), which leads to the change of gamma
rhythms and the impairment of cognitive functions observed in
patients suffered from schizophrenia. In addition, dysregulation
of the redox signaling pathway might provide an explanation
for the developmental origins of schizophrenia because there
appears to be a link between maternal viral infections dur-
ing gestation and the incidence of schizophrenia. During viral
infections, the increase of the IL-6 release and the resultant
activation of redox signaling pathway promote the hypofunc-
tion of NMDARs in the GABAergic interneurons (Berridge,
2013).
Recently, there are many reports that have shown that pos-
sible involvement of single-nucleotide polymorphisms (SNPs)
within two L-type voltage-gated calcium channel subunits,
CACNA1C and CACNB2, and neuropsychiatric disorders includ-
ing schizophrenia, suggesting that dysfunction of L-type voltage-
gated calcium channels occurs in patients with schizophrenia
(Ripke et al., 2013; Smoller et al., 2013). However, the activation
of voltage-gated calcium channels are well known to be sup-
pressed by the treatment of various antipsychotics (Santi et al.,
2002; Choi and Rhim, 2010). For example, in cultured HEK
cells, haloperidol acutely blocks T-type voltage-gated calcium
channels in a dose-dependent manner (Santi et al., 2002), while
it remains unclear whether antipsychotics also affect voltage-
gated calcium channels in neurons. Solís-Chagoyán et al. (2013)
recently reported that Ca2+ currents mediated by L-type voltage-
gated calcium channels recorded in olfactory neuroepithelial cells
obtained from patients with schizophrenia were 50% smaller
than those from healthy subjects. Because these patients with
schizophrenia were taking antipsychotics, the finding does not
simply support the genetic studies suggesting that dysfunction
of L-type voltage-gated calcium channels occurs in patients with
schizophrenia.
ANTIPSYCHOTICS AND THE ER-MEDIATED MICROGLIAL
INTRACELLULAR Ca2+ MOBILIZATION
Elevation of intracellular Ca2+ is also important for the activation
of microglia, including proliferation, migration, ramification,
deramification and release of NO, proinflammatory cytokines and
BDNF (Kettenmann et al., 2011). However, in microglial cells,
an application of high [K+]out or glutamate does not elevate
[Ca2+]i. This observation is supported by the fact that both
voltage-gated Ca2+ channels and NMDARs are not expressed in
microglia (Kettenmann et al., 2011). For electrically non-excitable
cells including microglia, the primary source of intracellular Ca2+
is the release from intracellular Ca2+ stores and the entry through
the ligand-gated and/or store operated Ca2+ channels (Möller,
2002). Microglia contain at least two types of intracellular Ca2+
stores: the ER and mitochondria. The main route for the gen-
eration of intracellular Ca2+ signaling is associated with inositol
1,4,5-trisphosphate (InsP3) receptors on the ER membrane. Stim-
ulation of G protein-coupled metabotropic receptors results in the
activation of the phospholipase C (PLC), production of two sec-
ond messengers including the diacylglycerol (DAG) and the InsP3
and the release of Ca2+ from the ER. Importantly, the depletion
of ER activates the store-operated Ca2+ entry (SOCE), known as
a capacitative Ca2+ influx, mediated by plasmalemmal channels
such as calcium release-activated Ca2+ (CRAC) channels and/or
transient receptor potential (TRP) channels (Parekh and Put-
ney, 2005). In addition, STIM1, one of ER membrane proteins,
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senses the filling state of ER Ca2+ and delivers the ER to the
plasma membrane where it directly activates Orai1/CRAC chan-
nels, thereby facilitating the re-uptake of Ca2+ to ER through
the sarco(endo)plasmic reticulum Ca2+-ATPases (SERCA). The
concentration of Ca2+ in the ER is precisely controlled by SERCA.
The influx of Ca2+ through the TRP channels plays an important
role in many inflammatory processes including the activation of
microglia (Nilius et al., 2007; Mizoguchi et al., 2014). Because
there is increasing evidence suggesting that pathophysiology of
schizophrenia is related to the inflammatory responses mediated
by microglia (Müller and Schwarz, 2007; Monji et al., 2013),
it could be important to examine the effects of antipsychotics
on the ER function of microglial cells for the treatment of
schizophrenia.
In some electrically non-excitable cells such as macrophages,
adipocytes, β-cells and oligodendrocytes, perturbation of the
calcium homeostasis in the ER results in the accumulation of
unfolded proteins, the induction of the ER stress response, the
promotion of the inflammatory processes and the initiation of
apoptosis (Zhang and Kaufman, 2008). Experimentally, the ER
stress response is frequently induced by selectively inhibiting
SERCA using agents such as thapsigargin (TG) which passively
deplete the ER (Thastrup et al., 1990). It remains unclear how
typical or atypical antipsychotics affect the ER-mediated intra-
cellular Ca2+ mobilization in microglia. Thus, we examined
how pretreatment with typical (haloperidol) or atypical (risperi-
done) antipsychotics affects TG-induced intracellular Ca2+ mobi-
lization, which represents a cellular stress response. In rodent
microglial cells, we observed that opposite effects of haloperidol
and risperidone on the TG-induced intracellular Ca2+ mobi-
lization (Mizoguchi et al., unpublished observations). There
are two other reports showing opposite effects of haloperidol
and risperidone on intracellular Ca2+ mobilization. In cultured
astrocytes derived from rat cortex and striatum, intracellular
Ca2+ imaging showed that pretreatment with risperidone but
not haloperidol suppressed the dopamine-induced increase in
[Ca2+]i (Reuss and Unsicker, 2001). In another study obtained
from rat PC12 cells, pretreatment with haloperidol potenti-
ated the rotenone-induced neurotoxicity, while risperidone sup-
pressed it. Likewise, pretreatment with haloperidol potentiated
the rotenone-induced increase in [Ca2+]i, while risperidone com-
pletely suppressed it, suggesting that opposite effects of haloperi-
dol and risperidone on rotenone-induced neurotoxicity could
be mediated by their differential effects on intracellular Ca2+
mobilization (Tan et al., 2007). In addition, Kurosawa et al.
(2007) reported that pretreatment with risperidone but not with
haloperidol suppressed the death of rat cultured cortical neu-
rons induced by treatment with TG for 72 h. Disruption of
intracellular Ca2+ signaling triggers the activation of cell death
programs (Orrenius et al., 2003). Treatment of primary cultured
microglial cells by TG or ionomycin induced cellular apopto-
sis and this pathway was suppressed by the pretreatment with
BAPTA-AM (Nagano et al., 2006). Thus, these suggest that typical
and atypical antipsychotics have different effects on the ER-
mediated intracellular Ca2+ mobilization, which might lead to
the differences in the actions of typical and atypical antipsy-
chotics on the induction of the ER stress response, promotion
FIGURE 1 | Schematic illustration representing the microglial
intracellular Ca2+ signaling, especially the ER function, as major
targets of antipsychotics for the treatment of schizophrenia. SERCA,
sarco(endo)plasmic reticulum Ca2+-ATPases; TG, thapsigargin; SOC,
store-operated calcium channel.
of the inflammatory responses and/or initiation of apoptosis in
microglia (Figure 1).
Brain-derived neurotrophic factor is also well known for
its involvement in the pathophysiology of neuropsychiatric
disorders including schizophrenia (Autry and Monteggia, 2012).
A recent meta-analysis of studies showed that blood levels of
BDNF are reduced in both medicated and drug-naïve patients
with schizophrenia (Green et al., 2011). In addition, expression
of BDNF in rodent microglia is important for the spine
elimination/formation and motor-learning processes (Parkhurst
et al., 2013). We have recently reported that BDNF induces
sustained [Ca2+]i elevation, which was mediated by an initial
PLC/InsP3-driven Ca2+ release from the ER that followed by a
long-lasting activation of the SOCE via the up-regulation of cell-
surface TRPC3 channels in rodent microglial cells (Mizoguchi
et al., 2009, 2014). In addition, incubation with BDNF decreased
release of NO from the activated microglia, suggesting that
BDNF might have an anti-inflammatory effect through the
inhibition of microglial activation and could be useful for the
treatment of neuropsychiatric disorders including schizophrenia.
It remains unclear how typical or atypical antipsychotics affect
the BDNF-mediated intracellular Ca2+ mobilization in microglia.
There is increasing evidence suggesting that pathophysiol-
ogy of schizophrenia is related to the inflammatory responses
mediated by microglia (Müller and Schwarz, 2007; Kato et al.,
2011; Monji et al., 2013; Myint and Kim, 2014). In addi-
tion, we have reported that pretreatment with antipsychotics
significantly inhibits the release of proinflammatory cytokines
and/or NO from activated microglial cells, possibly through
the suppression of [Ca2+]i elevation in microglial cells (Kato
et al., 2008, 2013; Mizoguchi et al., 2011). For electrically non-
excitable cells such as microglia, the primary source of intra-
cellular Ca2+ is the ER. suggesting the importance of the ER
as a therapeutic target of antipsychotics for the treatment of
schizophrenia.
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CONCLUSION
Microglia can release many factors including proinflammatory
cytokines, NO and BDNF when they are activated in response to
immunological stimuli. There is increasing evidence suggesting
that pathophysiology of schizophrenia is related to the inflam-
matory responses mediated by microglia. In addition, we have
previously reported that pretreatment with antipsychotics signif-
icantly inhibits the release of proinflammatory cytokines and/or
NO from activated microglial cells, possibly through the suppres-
sion of the elevation of [Ca2+]i, suggesting the importance of
microglial intracellular Ca2+ signaling as a target of antipsychotics
for the treatment of schizophrenia. Although the electrical activity
of neurons mainly depends on voltage-gated calcium channels
and NMDARs, the generation of intracellular Ca2+ signaling in
non-excitable cells such as microglia is mainly regulated by the
ER. These suggest the importance of the ER as a therapeutic target
of antipsychotics for the treatment of schizophrenia.
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